Sharda University, Nanoved Research Foundation announce successful clinical trials of HARAS for smokers’ lung protection, ET HealthWorld


New Delhi: Sharda University, in collaboration with Nanoved Research Foundation, has announced successful clinical trials of HARAS, a nanotechnology-based nutraceutical designed to protect smokers’ lungs by significantly reducing carbon monoxide (CO) levels. This breakthrough formulation utilises curcumin, a compound derived from turmeric, and offers a promising preventive measure against smoking-related diseases. The announcement coincides with World No Tobacco Day, underscoring the urgent need for effective interventions in smoking cessation and lung health protection.

Cigarette smoking remains a leading cause of lung cancer and other chronic diseases, with statistics showing it accounts for 90 per cent of lung cancer cases in men and 70–80 per cent in women. Smokers are 15 to 30 times more likely to develop lung cancer or succumb to it compared to non-smokers. In light of this, Dr Vijay Kanuru, Founder, Nanoved Research Foundation, have developed HARAS, a curcumin-based nutraceutical that boasts enhanced bioavailability through innovative nanotechnology.

Clinical trials, conducted by Sharda University’s researchers, including Dr Deepak Bhargava, Dr Vidya Devi Chandvarkar, and Dr Mithilesh Mishra, involved 25 healthy smoker volunteers who were administered 10ml of HARAS juice daily for 30 days. CO levels were meticulously monitored using a breath analyser at the beginning, mid-point, and conclusion of the trial. Results revealed a statistically significant reduction in CO levels by the 30th day (P
Dr Deepak Bhargava, Professor and Head, Department of Oral Pathology and Microbiology, Sharda University, said, “Our clinical studies demonstrate that HARAS provides substantial lung protection for smokers by significantly reducing carbon monoxide levels. This nutraceutical stands as a crucial tool in combating the adverse health effects of smoking.”

Dr Mithilesh Mishra, Associate Professor, Sharda University, noted, “In our extended study with 100 smoker patients, HARAS showed no side effects while significantly reducing CO levels, confirming its safety and efficacy.”

Dr Kanuru remarked, “By utilising liposomal nanotechnology, we have vastly improved the bioavailability of curcumin, allowing even small doses to offer significant health benefits. HARAS is not only beneficial for smokers but also provides protection against conditions induced by air pollution, such as fatigue, inflammation, and cardiovascular issues.”

Dr Pradyut Waghray, Pulmonologist, Apollo Hospitals Hyderabad, added, “HARAS’s capacity to mitigate cigarette smoke-induced pulmonary inflammation and oxidative stress marks it as a vital preventive measure for millions of smokers.”

HARAS operates by leveraging curcumin’s potent antioxidant and anti-inflammatory properties. Curcumin effectively reduces inflammatory signals and oxidative stress caused by cigarette smoke, thereby protecting lung tissues. The proprietary nanoformulation ensures that curcumin is efficiently absorbed by the body, maximising its therapeutic effects.

The development and successful validation of HARAS signify a major advancement in preventive healthcare. By significantly reducing CO levels in smokers, HARAS can help mitigate the risks of lung cancer and other smoking-related diseases. This nutraceutical offers a non-invasive, safe, and effective approach to improving lung health and reducing healthcare burdens. HARAS is particularly beneficial for marginalised populations, providing an accessible solution to combat the detrimental health effects of smoking and air pollution. Announcing these findings on World No Tobacco Day underscores the urgent need for innovative solutions to address global tobacco-related health challenges.

The innovative and clinically validated HARAS formula is available in two convenient forms: over-the-counter (OTC) as a liquid juice and by prescription as capsules. This dual availability ensures that HARAS can be easily accessed by a broad range of individuals. General physicians and pulmonologists can prescribe HARAS capsules, making it a versatile addition to treatment plans aimed at reducing the harmful effects of smoking.

  • Published On May 30, 2024 at 09:53 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles

Scan to download App


Leave a Reply

Your email address will not be published. Required fields are marked *